Outsourced Pharma Webinars

  1. Leveraging Machine Learning For Decision Making In The Lab 11/27/2017

    This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.

  2. Looking Under The Hood Of The Unified Lab 11/22/2017

    Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.

  3. Solvents, Polymers & Cyclones: Bioavailability Enhancement Through Spray-Dried Dispersions 11/2/2017

    Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed. Learn how spray-dried amorphous dispersion might help.

  4. Challenges And Opportunities In The Development Of Biologic Drugs 7/20/2017

    With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.

  5. Optimize Biologic Drug Development With The Power Of Scientific Informatics 7/20/2017

    The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.

  6. Should Your Next Clinical Trial Use A New Supply Model? 5/26/2017

    Clinical supply models need to provide for an adequate supply of patient kits that allow for variations in patient recruitment levels and clinical site activity.

  7. Visibility and Oversight: What Paper Informed Consent Isn’t Offering You (Featuring Guest Speaker, Chesapeake IRB) 3/8/2017

    Chesapeake IRB and CRF Health team up for a collaborative webinar to discuss informed consent oversight and visibility and why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.

  8. The World’s Best eCOA Body Map: How Patients Improved Symptom Location Reporting 3/7/2017

    The burden of ineffective and inefficient body maps creates risks that can impact data quality. We knew we could come up with something much better - for all stakeholders.

  9. An Alternative To Achieve Speed And Scalability To Microbial Expression For Next-Gen Therapeutics 2/17/2017

    The newly developed G1-3 fermentation process makes use of short, straightforward fermentation regimes for optimized space time yield.

  10. Integrating Safety And Immunogenicity Assessments Into The Biopharma Preclinical Development Process 9/27/2016

    Efficacy, safety, immunogenicity and manufacturability issues play a large role in the high attrition rate of biopharmaceutical candidates each year. To help reduce the risk of failure, tools to address the developability of preclinical candidates have been established.